The reiteration of the Overweight rating suggests continued confidence in Moderna's long-term prospects. However, the significant reduction in the price target from $214 to $157 indicates a more cautious short-term outlook, likely due to recent performance or market conditions. This mixed signal could lead to short-term downward pressure on the stock price.